Endocyte (ECYT)
Endocyte Current Ratio: 19.80
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
ECYT Current Ratio Rankings
| Overall | 98th percentile | 61 of 4373 |
| Sector | 97th percentile | 13 of 503 in Healthcare |
| Industry | 88th percentile | 3 of 25 in Drug Manufacturers - Major |
ECYT Current Ratio Range, Past 5 Years
| Minimum | 0.0421 | Dec 2009 |
| Maximum | 25.59 | Sep 2011 |
| Average | 12.85 |
About Current Ratio
The current ratio measures a company's ability to pay short-term debts and other current liabilities (financial obligations lasting less than one year) by comparing current assets to current liabilities. Current assets are cash and any assets expected to be converted into cash within the next year. The ratio illustrates a company's ability to remain solvent.
A current ratio of 1 means that book value of current assets is exactly the same as book value of current liabilities. In general, investors look for a company with a current ratio of 2:1, meaning that it has twice as many current assets as current liabilities. A current ratio less than one indicates the company might have problems meeting short-term financial obligations. If the ratio is too high, the company may not be efficiently using its current assets or short term financing facilities.
Learn More
You may also be interested in these ECYT related companies
ECYT News
Ann Hanham, Dir, Audit Cmte Member of Nominating & Corporate Gov Cmte
HAS UNLOADED almost 200k shares...hmmmm...what does she know...$ECYT
about 5 days ago by escarleto
about 5 days ago by escarleto
if $ECYT doesn't gap up I dont think it will run tomorrow...need vol
about 5 days ago by Newbie_Trader
about 5 days ago by Newbie_Trader
RT @Newbie_Trader $ECYT I called this yesterday..no position but id go long// you called a 1 cent pop? Nice. Go long, man. Do it!
about 6 days ago by El_tercero
about 6 days ago by El_tercero
@LTbioinvestor $ECYT i don't think avg down is a good idea here right now.
about 6 days ago by escarleto
about 6 days ago by escarleto
$ECYT director sold more shares here at the low $6 level. it this fails to hold $6 will be another great short opportunity
about 6 days ago by escarleto
about 6 days ago by escarleto
$ECYT Almost pulled trigger on $ECYT today, but insiders are selling and well...looks like bleeding will continue below 50
about 6 days ago by escarleto
about 6 days ago by escarleto
@missyaubaby what do you think of $ECYT? looks like it could pop soon.. thoughts?
about 7 days ago by Newbie_Trader
about 7 days ago by Newbie_Trader
$ECYT Insider Sale: $1M of stock sold by Ann Hanham between May 14, 2012 - May 15, 2012 http://stks.co/3rZ5
about 12 days ago by MarketBrief
about 12 days ago by MarketBrief
Endocyte and Oncothyreon Look to Benefit From Enhancements to U.S. Patent System
May 15, 8:20AM Marketwire
May 15, 8:20AM Marketwire
Listen to $ECYT Q1 2012 earnings call - live at 04:30 PM, ondemand after - http://stks.co/3mBe
about 18 days ago by earningscast
about 18 days ago by earningscast
Endocyte Reports First Quarter 2012 Financial Results and Operations Update
May 10, 4:00PM GlobeNewswire
May 10, 4:00PM GlobeNewswire
$ECYT nice bounce off 4.79 lod, has plenty more here. plenty value just oversold into the down day, these are the best buy ops. 7.25+ coming
about 25 days ago by QR_Winner
about 25 days ago by QR_Winner
$ECYT 7 break here. I wouldn't wait till next week to buy when everyone will be. imo this is buying op
about 25 days ago by QR_Winner
about 25 days ago by QR_Winner
Data on Endocyte's Vintafolide and Etarfolatide to be Presented at the 3rd European Lung Cancer Conference
Apr 20, 4:00PM GlobeNewswire
Apr 20, 4:00PM GlobeNewswire
Baird Lifts Price Target on Endocyte (ECYT) Following Transformational Merck Deal
Apr 16, 10:55AM Street Insider
Apr 16, 10:55AM Street Insider
Endocyte (ECYT) Gets WHO, USAN Approval for 'Vintafolide' and 'Etarfolatide' Names on EC145, EC20
Mar 22, 4:05PM Street Insider
Mar 22, 4:05PM Street Insider
Endocyte Receives USAN Approval for Nonproprietary Names of Novel Endocyte Drug Candidates
Mar 22, 4:03PM Benzinga
Mar 22, 4:03PM Benzinga
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| ECYT | 6.30 | +0.02 | +0.32% | 225.16M |
| ECPG | 24.16 | -0.07 | -0.29% | 592.40M |
| ECL | 64.35 | -0.74 | -1.14% | 18.78B |
| ECHO | 17.01 | +0.19 | +1.13% | 379.83M |
| ECH | 59.29 | +0.28 | +0.47% | |
| ECF | 6.88 | -0.01 | -0.13% | |
| ECA | 20.50 | +0.24 | +1.18% | 15.08B |
| EC | 57.73 | +0.42 | +0.73% | 118.68B |
| EBTX | 20.51 | +0.03 | +0.15% | 243.25M |
| DTV | 46.40 | +0.03 | +0.06% | 31.39B |
